<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548349</url>
  </required_header>
  <id_info>
    <org_study_id>1234</org_study_id>
    <nct_id>NCT04548349</nct_id>
  </id_info>
  <brief_title>Profiling the Skin Microbiome in Response to Altreno in Acne Patients</brief_title>
  <official_title>Profiling the Skin Microbiome in Response to Altreno in Acne Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Dermatologics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to characterize the shift in the diversity and abundance of the skin&#xD;
      microbial community at baseline and in response to Altreno monotherapy as compared to benzoyl&#xD;
      peroxide (BPO) 2.5% leave-on gel monotherapy in acne patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the advent of 16S rRNA sequencing, scientific community is beginning to understand the&#xD;
      critical importance of the microbiome in human health. In dermatology, researchers have begun&#xD;
      to lead the effort to not only better understand how the microbiome contributes to the&#xD;
      pathogenesis of skin disease, but also harness its power to develop novel therapies. Acne is&#xD;
      a common inflammatory skin disorder. P. acnes on the skin has been traditionally thought of&#xD;
      as the culprit bacteria in the pathogenesis of acne.&#xD;
&#xD;
      Recent studies demonstrate that the skin microbial composition dynamically changes in&#xD;
      response to systemic acne therapy. Using 16 rRNA gene sequencing, a prior study has confirmed&#xD;
      that systemic antibiotic treatment decreased the abundance of P. acnes, which returned to&#xD;
      baseline after discontinuation of the therapy. In contrast, the systemic therapy increased&#xD;
      the abundance of Pseudomonas species, which returned to baseline after therapy cessation.&#xD;
      Based on the opposing response to the therapy, it can be speculated that these two species&#xD;
      compete for the same microenvironment within the skin microbiome. Interestingly, the same&#xD;
      systemic therapy decreased the abundance of lactobacillus genus, the &quot;good bacteria&quot; that is&#xD;
      protective against skin infection, and that decrease was sustained even after cessation of&#xD;
      the therapy. Similarly, another study has demonstrated that systemic isotretinoin therapy&#xD;
      disturbed the skin microbiome in acne patients with increased bacterial diversity on the&#xD;
      cheeks. It is unclear the potential therapeutic role of the increased bacterial diversity in&#xD;
      the management of acne patients.&#xD;
&#xD;
      The study aims to characterize the shift in the diversity and abundance of the skin microbial&#xD;
      community in response to Altreno in acne patients. Understanding the role of the skin&#xD;
      microbiome in response to therapy can help clinicians to develop tailored, targeted treatment&#xD;
      options, including reconstitution of &quot;good bacteria.&quot; Furthermore, it can lead to development&#xD;
      of novel topical pre and probiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the diversity of the skin microbiome before and after the treatment with Altreno.</measure>
    <time_frame>Completion of study 120 days</time_frame>
    <description>The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index of the bacterial DNA in the skin microbiome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the diversity of the skin microbiome before and after the treatment with Altreno.</measure>
    <time_frame>Completion of study 120 days</time_frame>
    <description>The diversity will be evaluated by assessing the Shannon diversity of the bacterial DNA in the skin microbiome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the diversity of the skin microbiome before and after the treatment with BPO therapy.</measure>
    <time_frame>Completion of study 120 days</time_frame>
    <description>The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index of the bacterial DNA in the skin microbiome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the diversity of the skin microbiome before and after the treatment with BPO therapy.</measure>
    <time_frame>Completion of study 120 days</time_frame>
    <description>The diversity will be evaluated by assessing the Shannon diversity of the bacterial DNA in the skin microbiome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Leeds score</measure>
    <time_frame>120 days</time_frame>
    <description>Score range is grade 1 to grade 12. Higher scores indicate a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the lesion count of inflammatory and non-inflammatory</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acne</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Altreno Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPO Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>During the entire study period, the subjects in the control group will not be allowed to use any antibacterial wash, other than approved OTC cleansers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Altreno</intervention_name>
    <description>Acne patients will be assigned to Altreno once daily.</description>
    <arm_group_label>Altreno Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl peroxide</intervention_name>
    <description>Acne patients will be assigned to BPO leave-on gel once daily.</description>
    <arm_group_label>BPO Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A confirmed diagnosis of acne that warrants initiating topical medications.&#xD;
&#xD;
          -  Denies use of any prescribed systemic acne treatments in the past 30 days.&#xD;
&#xD;
          -  Denies use of any prescribed topical medications in the past 30 days.&#xD;
&#xD;
          -  Denies use of any OTC topical acne medications in the past 14 days.&#xD;
&#xD;
          -  Denies use of any emollients in the past 24 hours (if feasible).&#xD;
&#xD;
          -  Denies bathing or facial washing in the past 12 hours (if feasible).&#xD;
&#xD;
          -  Willingness to adhere to the recommended topical regimen during the duration of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding, or planning to get pregnant during the study.&#xD;
&#xD;
          -  Use of any investigational drug(s) in the past 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Principal Investigator</last_name>
    <phone>617-667-5201</phone>
    <email>jmcgee2@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deacones Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. McGee</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chien AL, Tsai J, Leung S, Mongodin EF, Nelson AM, Kang S, Garza LA. Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics. JAMA Dermatol. 2019 Apr 1;155(4):425-434. doi: 10.1001/jamadermatol.2018.5221.</citation>
    <PMID>30758497</PMID>
  </reference>
  <reference>
    <citation>Kelhälä HL, Aho VTE, Fyhrquist N, Pereira PAB, Kubin ME, Paulin L, Palatsi R, Auvinen P, Tasanen K, Lauerma A. Isotretinoin and lymecycline treatments modify the skin microbiota in acne. Exp Dermatol. 2018 Jan;27(1):30-36. doi: 10.1111/exd.13397. Epub 2017 Sep 14.</citation>
    <PMID>28636791</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Jean S. McGee, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

